Abstract
Opinion statementColorectal cancer (CRC) imposes significant morbidity and mortality, yet it is also largely preventable with evidence-based screening strategies. In May 2021, the US Preventive Services Task Force updated guidance, recommending screening begin at age 45 for average-risk individuals to reduce CRC incidence and mortality in the United States (US). The Task Force recommends screening with one of several screening strategies: high-sensitivity guaiac fecal occult blood test (HSgFOBT), fecal immunochemical test (FIT), multi-target stool DNA (mt-sDNA) test, computed tomographic (CT) colonography (virtual colonoscopy), flexible sigmoidoscopy, flexible sigmoidoscopy with FIT, or traditional colonoscopy. In addition to these recommended options, there are several emerging and novel CRC screening modalities that are not yet approved for first-line screening in average-risk individuals. These include blood-based screening or “liquid biopsy,” colon capsule endoscopy, urinary metabolomics, and stool-based microbiome testing for the detection of colorectal polyps and/or CRC. In order to maximize CRC screening uptake in the US, patients and providers should engage in informed decision-making about the benefits and limitations of recommended screening options to determine the most appropriate screening test. Factors to consider include the invasiveness of the test, test performance, screening interval, accessibility, and cost. In addition, health systems should have a programmatic approach to CRC screening, which may include evidence-based strategies such as patient education, provider education, mailed screening outreach, and/or patient navigation, to maximize screening participation.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Reference74 articles.
1. •• Lin JS, Perdue LA, Henrikson NB, Bean SI, Blasi PR. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021;325(19):1978–98. This evidence report systematically reviews the effectiveness, test accuracy, and harms of various colorectal cancer (CRC) screening tests. The review was used by the United States Preventive Services Task Force (USPSTF) to inform the 2021 USPSTF CRC screening recommendations. The authors provide quantitative data that allows healthcare providers to determine the best screening method for their patients.
2. Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, et al. Colorectal cancer incidence patterns in the United States, 1974-2013. J Natl Cancer Inst. 2017;109(8):djw322.
3. •• Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol. 2021;116(3):458–79. This article provides the American College of Gastroenterology’s updated colorectal cancer (CRC) screening guidelines. It discusses the efficacy of various screening modalities and outlines how screening recommendations differ for high-risk and average-risk individuals. Additionally, it discusses features of high-quality colonoscopy and different approaches for improving CRC screening adherence, including mailed fecal immunochemical test kits, patient navigation, and patient reminders.
4. •• Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, et al. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965–77. This systematic review was commissioned by the United States Preventive Services Task Force (USPSTF) to inform the 2021 colorectal cancer (CRC) screening recommendations. The USPSTF recommends that all average-risk adults age 45 to 49 (Grade B recommendation) and age 50 to 75 (Grade A recommendation) undergo screening; screening for individuals age 76 to 85 should be based on patient-provider discussions of harms and benefits. The recommendation to initiate screening at age 45 is based on modeling data for estimated life-years gained, CRC incidence, and CRC mortality if screening is started at varying ages. This manuscript also summarizes recommended screening modalities and intervals.
5. • Knudsen AB, Rutter CM, Peterse EFP, Lietz AP, Seguin CL, Meester RGS, et al. Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force. JAMA. 2021;325(19):1998–2011. This publication is a comparative modeling study that uses three microsimulation models of colorectal cancer (CRC) screening in a hypothetical cohort to provide updated model-based estimates of the benefits and harms of CRC screening strategies and to identify strategies that may provide an efficient balance of life-years gained from screening and colonoscopy burden. The study was commissioned by the United States Preventive Services Task Force to inform the 2021 CRC screening recommendations.